Outcomes Data For Sanofi/Regeneron’s Praluent May Land In 2016
This article was originally published in The Pink Sheet Daily
Interim analyses from the events-driven trial of the PCSK9 inhibitor may be available next year, helping to pave the way for broader labeling.
You may also be interested in...
With a well-defined mechanism of action and positive post hoc outcomes data, PCSK9 inhibitors possess a profile that raises the bar for other non-statin classes – CETP in particular.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.